What is your preferred PMRT dose/fractionation for patients with implant reconstruction?

Topics: Breast Cancer • Radiation Oncology • ASTRO 2023

Did your treatment inclinations change with the results of the recent FABREC trial (NCT03422003) presented at ASTRO?

Answer from: Radiation Oncologist at Academic Institution

I stated in a post in July 2022, that I switched to using hypofractionation for patients with both autologous and implant-based reconstructions after the FABREC trial closed, which we participated in. The results of FABREC presented at ASTRO showed no significant difference between the hypofractiona...

Comments

Radiation Oncologist at Palo Alto Medical Foundation
Thank you for participating in this study and comm...

Radiation Oncologist at Beth Israel Deaconess Medical Center
I can't go into the trial results more. However, m...

Related Questions